Although surrogate endpoints enable faster trials and therefore faster access to treatment, they increase the uncertainty of coverage decisions on health technologies |
Our survey shows that many international health technology assessment (HTA) agencies currently lack detailed guidance for the evaluation of health technologies that rely on surrogate endpoint evidence |
HTA agencies need to provide more detailed and prescriptive guidelines for the consistent qualification and incorporation of surrogate endpoint evidence in the decision processes where the evidence on patient-relevant endpoints is lacking |
Current best knowledge suggests that adequate approaches include evidence hierarchy frameworks, meta-regression analytical techniques and economic modelling methods that explicitly explore the uncertainty in the surrogate-to-final endpoint relationship |
1 Background
2 Methods
2.1 Identification of Health Technology Assessment (HTA) Agencies
2.2 Document Review and Data Extraction
2.3 Stage 1: Identification of HTA Agency Methods Guidance on the Use of Surrogate Endpoints
2.4 Stage 2: Detailed Analysis of Surrogate Methodological Advice
Domain | Explanation |
---|---|
Definition | Is a definition of surrogate endpoints provided as part of the document? |
Examples | Are examples of surrogate endpoints provided in the text of the document (e.g. progression-free survival as a surrogate endpoint for overall survival)? |
Use of surrogates considered | Are considerations on the use of surrogate endpoints included in the guidelines, such as recommendations to caution when including surrogate endpoints in the analysis? |
Acceptability criteria | Are acceptability criteria included in the guidelines (e.g. requirements to validate the surrogate endpoint used)? |
Evidence strength assessment | Is there a framework for quantifying the evidence on the surrogate–final outcome relationship? Level 1—evidence demonstrating that treatment effects on the surrogate correspond to effects on the patient-related outcome (from clinical trials); level 2—evidence demonstrating a consistent association between surrogate outcome and final patient-related outcome (from epidemiological/observational studies); level 3—evidence of the biological plausibility of the relationship between surrogate outcome and final patient-related outcome (from pathophysiological studies and/or understanding of the disease process) |
Validation methods | Are any validation methods prescribed (e.g. correlation of the effects on the surrogate endpoint and the effects on the clinical endpoint from meta-analysis of randomised trials)? |
Validation values | Are accepted cut-off values of the surrogate endpoint-to-final outcome association presented? |
2.5 Data Analysis and Presentation
3 Results
3.1 Selection of HTA Agencies
Country | Acronym | Institution name | Language | Guidelines | Surrogate outcomes guidelines | |
---|---|---|---|---|---|---|
English | Originala | |||||
Austria | HVB | Main Association of Austrian Social Security Institutions | Hauptverband der Österreichischen Sozialversicherungstrager | German | Yes | No |
Austria | HVSV-HEK | Federation of the Austrian Social Insurance Institutions—Medicines Evaluation Commission | Hauptverband der österreichen Sozialversicherungsträger—Heilmittel-Evaluierungskommission | German (mostly) | Yes | No |
Austria | LBI-HTA | Ludwig Boltzmann Institute for Health Technology Assessment | Ludwig Boltzmann Institut für Health Technology Assessment | English | Yes | Yes |
Austria | GÖG | Austrian Health Institute | Gesunheit Österreich GmbH | English | Yes | No |
Australia | MSAC | Medical Services Advisory Committee | English | Yes | Yes | |
Australia | PBAC | Pharmaceutical Benefits Advisory Committee | English | Yes | Yes | |
Belgium | IPHb | Scientific Institute of Public Health | Sciensano | English | Yes | No |
Belgium | KCE | Belgian Federal Health Care Knowledge Centre | Federaal Kenniscentrum voor de Gezondheidszorg | English | Yes | Yes |
Belgium | RIZIV-INAMI | National Institute for Health Insurance | Rijksinstituut voor Ziekte- en Invaliditeitsverzekering | French | Noc | No |
Bulgaria | NCPHA | National Centre of Public Health Protection | Haциoнaлeн цeнтъp пo oбщecтвeнo здpaвe и aнaлизи | Bulgarian | Yes | Yes |
Canada | CADTH | Canadian Agency for Drugs and Technologies in Health | English | Yes | Yes | |
Central and Eastern Europe (Poland) | CEESTAHC | Central and Eastern European Society of Technology Assessment in Health Care | Polish | No | No | |
Croatia | AAZ | Agency for Quality and Accreditation in Health Care and Social Welfare | Agencija za kvalitetu i akreditaciju u zdravstvu i socijalnoj skrbi | Croatian | Yes | Yes |
Croatia | CHIF | Croatian Health Insurance Fund | Hrvatski zavod za zdravstveno osiguranje | Croatian | No | No |
Croatia | CIPH | Croatian Institute of Public Health | Hrvatski zavod za javno zdravstvo | Croatian | No | No |
Cyprus | MoH CY | Ministry of Health of Cyprus | Υπουργείο Υγειας | Greek | No | No |
Czech Republic | MoH CZ | Czech Republic Ministry of Health | Ministerstvo zdravotnictví ČR | English | No | No |
Czech Republic | SUKL | State Institute for Drug Control | Státní ústav pro kontrolu léčiv | English (mostly) | Yes | No |
Denmark | DEFACTUM | DEFACTUM | DEFACTUM | English, Danish | Yes | No |
EU | EUnetHTA | European Network for Health Technology Assessment | English | Yes | Yes | |
Finland | FIMEA | Finnish Medicines Agency | Lääkealan turvallisuus- ja kehittämiskeskus | English, Finnish | No | No |
Finland | FinCCHTA | Finnish Coordinating Center for Health Technology Assessment | Kansallinen HTA-koordinaatioyksikkö | Finnish | Yes | No |
Finland | FinOHTA | Finnish Office for Health Technology Assessment | Terveydenhuollon menetelmien arviointiyksikkö | English, Finnish | Yes | No |
Finland | LH | Pharmaceuticals Pricing Board | Lääkkeiden hintalautakunta | English, Finnish | No | No |
France | HAS | High Health Authority | Haute Autorité de Santé | French | Yes | Yes |
Germany | DAHTA @ DIMDI | German Agency for HTA at the German Institute for Medical Documentation and Information | Deutsche Agentur für Health Technology Assessment | German | Yes | Yes |
Germany | G-BA | The German Federal Health Care Joint Committee | Gemeinsame Bundesausschuss | German | Yes | Yes |
Germany | IQWiG | Institute for Quality and Efficiency in Health Care | Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen | German | Yes | Yes |
Germany | TAB | Office of Technology Assessment | Büro für Technikfolgen-Abschätzung beim Deutschen Bundestag (TAB) | English | No | No |
Greece | EOF | National Organization for Medicines | Εθνικός Οργανισμός Φαρμάκων | Greek | No | No |
Greece | EOPPY | National Organisation for Healthcare Provision | ΕΟΠΥΥ | Greek | Yes | Yes |
Hungary | NIPN | National Institute of Pharmacy and Nutrition | Országos Gyógyszerészeti és Élelmezés-egészségügyi Intézet | Hungarian | Yes | Yes |
Ireland | HIQA | Health Information and Quality Authority | English | Yes | Yes | |
Ireland | NCPE | National Centre for Pharmacoeconomics, St. James Hospital | National Centre for Pharmacoeconomics, St. James Hospital | English | No | No |
Italy | Age.Na.S | National Agency for Regional Health Services | Agenzia nazionale per i servizi sanitari regionali | Italian | Yes | No |
Italy | AIFA | Italian Medicine Agency | Agenzia Italiana Del Farmaco | Italian | Yes | Yes |
Italy | Arsenàl.IT | Veneto's Research Center for eHealth Innovation | Centro Veneto Ricerca e Innovazione per la Sanità Digitale | Italian | No | No |
Italy | ASSR | Regional Observatory for Innovation—Regional Agency for Health and Social Care | Osservatorio regionale per l'innovazione—Agenzia sanitaria e sociale regionale—Regione Emilia-Romagna | Italian | No | No |
Italy | DGFDM IT | Italian Ministry of Health | Sede del Ministro—Ministero della salute | Italian | No | No |
Italy | UVTA/AOP | HTA Unit in A. Gemelli Teaching Hospital | Unità di Valutazione delle Tecnologie (UVT), Policlinico Universitario “Agostino Gemelli” | Italian | Yes | Yes |
Latvia | SAMLV | Zāļu valsts aģentūra | The State Agency of Medicines | Latvian (mostly) | No | No |
Lithuania | HI LT | The Institute of Hygiene | Higienos institutas | English | No | No |
Lithuania | VASPVT | State Health Care Accreditation Agency under the Ministry of Health of the Republic of Lithuania | Valstybinė akreditavimo sveikatos priežiūros veiklai tarnyba | English (some) | No | No |
Malta | DPA/MoH Malta | Directorate for Pharmaceutical Affairs | English | No | No | |
Norway | Hdir | Norwegian Directorate of Health | Helsedirektoratet | English (some) | No | No |
Norway | NIPH | Formerly NOKC—The Norwegian Institute of Public Health | Nasjonalt kunnskapssenter for helsetjenesten | English | Yes | Yes |
Norway | NOMA | Norwegian Medicines Agency | Statens legemiddelverk | Norwegian | Yes | No |
Poland | AOTMiT | Agency for Health Technology Assessment and Tariff System | Agencja Oceny Technologii Medycznych i Taryfikacji, Agency for Health Technology Assessment and Tariff System | Polish | Yes | Yes |
Portugal | ACSS IP | Administração Central do Sistema de Saúde, I.P | Administração Central do Sistema de Saúde, I.P | English (mostly) | No | No |
Portugal | INFARMED | National Authority of Medicines and Health Products | Autoridade Nacional do Medicamento e Produtos de Saúde | Portuguese | Yes | Yes |
Romania | NSPHMPDB | National School of Public Health, Management and Professional Development | Scoala Nationala de Sanatate Publica, Management si Perfectionare in Domeniul Sanitar | English, Romanian | No | No |
Slovakia | MoH SK | Ministry of Health of the Slovak Republic | Úrad verejného zdravotníctva Slovenskej republiky | Slovak (mostly) | Yes | Yes |
Slovenia | JAZMP | Public Agency of the Republic of Slovenia for Medicinal Products and Medical Devices | Javna agencija Republike Slovenije za zdravila in medicinske pripomočke | Slovenian | No | No |
Slovenia | NIJZ | National Institute of Public Health | Nacionalni inštitut za javno zdravje | English | No | No |
Spain | AEETS | Spanish Association of Health Technology Evaluation | Asociación Española de Evaluación de Tecnologías Sanitarias | Spanish | Yes | Yes |
Spain | AETSA | Andalusian Agency for Health Technology Assessment | Agencia de Evaluación de Tecnologías Sanitarias de Andalucía | Spanish | Yes | Yes |
Spain | AQuAS | Agency for Health Quality and Assessment of Catalonia | Agència de Qualitat i Avaluació Sanitàries de Catalunya | Spanish | No | No |
Spain | AVALIA-T | Galician Agency for HTA | Avaliación de Tecnoloxías Sanitarias de Galician | Spanish | Yes | Yes |
Spain | DGFPS MSPSI | Directorate General for Pharmacy and Health Care Products | Secretaría General de Sanidad y Consumo | Spanish | No | No |
Spain | FPS | Andalusian Public Foundation Progress and Health | Fundación Pública Andaluza Progreso y Salud | Spanish | No | No |
Spain | OSTEBA | Basque Office for Health Technology Assessment—Ministry for Health | Servicio de Evaluación de Tecnologías Sanitarias | English, Spanish | No | No |
Spain | SESCS | Evaluation AND Planning Unit—Directorate of the Canary Islands Health Service | Servicio de Evaluación y Planificación, Canarias | Spanish | No | No |
Sweden | SBU | Swedish Council on Technology Assessment in Health Care | Statens beredning för medicinsk utvärdering | English | Yes | Yes |
Sweden | TLV | Dental and Pharmaceutical Benefits Agency | Tandvårds- och läkemedelsförmånsverket | English (some) | Yes | Yes |
Switzerland | MTU-SFOPH | Medical Technology Unit—Swiss Federal Office of Public Health | Bundesamt für Gesundheit BAG | French, German | Yes | No |
The Netherlands | ZIN | National Health Care Institute | Zorginstituut Nederland | English | Yes | Yes |
The Netherlands | ZonMwd | The Netherlands Organisation for Health Research and Development | English | No | No | |
UK | AWMSG | All Wales Medicines Strategy Group | English | Yes | Yes | |
UK | AWTTC | All Wales Therapeutics and Toxicology Centre | English | No | No | |
UK | HIS | Healthcare Improvement Scotland | English | Yes | No | |
UK | HTW | Health Technology Wales | Technoleg Iechyd Cymru | English | Yes | No |
UK | NICE | National Institute for Health and Clinical Excellence | English | Yes | Yes | |
UK | SMC | Scottish Medicines Consortium | English | Yes | No |
3.2 Consideration of Surrogate Endpoints
Use of surrogates considered? | Yes (dedicated document) Surrogate endpoints “should be adequately validated: the surrogate–final endpoint relationship must have been demonstrated based on biological plausibility and empirical evidence.” |
Surrogate definition provided? | Yes “A surrogate endpoint is an endpoint that is intended to replace a clinical endpoint of interest that cannot be observed in a trial—it is a variable that provides an indirect measurement of effect in situations where direct measurement of clinical effect is not feasible or practical. (ICH guideline E9, Statistical Principles for Clinical Trials, 1998) A surrogate endpoint may be a biomarker that is intended to substitute for a clinical endpoint. A surrogate endpoint may also be a clinical endpoint that is used to replace the endpoint of interest, such as an intermediate clinical endpoint.” “A biomarker can be defined as a characteristic that is objectively (reliably and accurately) measured and evaluated as an indicator of normal biological processes, pathogenic processes, or pharmacologic responses to an intervention” (Biomarkers Definitions Working Group, 2001) “An intermediate endpoint is a clinical endpoint such as measure of a function or of a symptom (disease-free survival, angina frequency, exercise tolerance) but is not the ultimate endpoint of the disease, such as survival or the rate of irreversible morbid events (stroke, myocardial infarction)” (Temple et al. 1999) |
Examples of surrogates listed? | Yes Example of surrogate endpoints: biomarkers (e.g. cholesterol level, HbA1c); examples of intermediate endpoints: disease-free survival, angina frequency, exercise tolerance |
Acceptability criteria provided? | Yes “Before a biomarker can be accepted as a surrogate endpoint, there is a need to have confidence that changes in the biomarker reliably predict changes in the desired clinical endpoints” (EMA, 2007) |
Evidence strength assessment provided? | Yes “The evidence for the validation of the surrogate–final outcome relationship has been presented by taking into account the level of evidence: Level 1: evidence demonstrating that treatment effects on the surrogate endpoint correspond to effects on the patient-related clinical outcome (from clinical trials); comprises a meta-analysis of several RCTs and establishment of correlation between effects on the surrogate and clinical endpoint Level 2: evidence demonstrating a consistent association between surrogate endpoint and final patient-related endpoint (from epidemiological/observational studies); and Level 3: only evidence of biological plausibility of relationship between surrogate endpoint and final patient-related endpoint (from pathophysiological studies and/or understanding of the disease process)” |
Validation methods provided? | Yes While the guidelines state that “currently, there is no systematic, transparent and widely agreed-upon process of biomarker validation”, they quote correlation of the effects on the surrogate and the effects on the clinical endpoint based on meta-analyses of several RCTs, as well as the surrogate threshold effect [39] The document offers a selected bibliography addressing the statistical methods of surrogate validation |
Validation values provided? | Yes Although only for information purposes: “There is no clear consensus of which correlation values are sufficient to assume adequate surrogacy, but values of between about 0.85 and 0.95 are often discussed” |
3.2.1 Definition for Surrogate Endpoints
3.2.2 Example of Surrogate Endpoints
3.2.3 Acceptability of Surrogate Endpoints
3.3 Detailed Methodological Guidance on Surrogate Endpoints
3.3.1 Methods for Validation of Surrogate Endpoints
Agency | Methods for validation of surrogate endpoints | Cut-offs for the acceptance of surrogate endpoints |
---|---|---|
MSAC (Australia) | MSAC propose a three-step approach to validate the transformation of a surrogate endpoint to estimate final outcomes: Step 1 requires a systematic review “to examine whether epidemiological evidence and biological reasoning has established that there is a relationship between the surrogate outcome and the final outcome independent of any intervention” Step 2 requires a systematic review “to examine whether direct randomised trial evidence using other active medical services has shown that there is a basis to conclude that a treatment effect on the surrogate outcome has satisfactorily predicted a treatment effect on the final outcome. […] Based on this evidence, quantify the relationship between these treatment effects with an assessment of the uncertainty of the relationship” Step 3 requires an explanation “why this relationship between the treatment effects on these outcomes with these other active medical services is likely to apply to the proposed therapeutic medical service. […] At present, it is difficult to give categorical advice” [23] | Not reported |
PBAC (Australia) | PBAC propose a four-step approach to validating the use of a surrogate endpoint to predict a final outcome: “A5.1—Define the PSM and the TCO A5.2—Establish the biological reasoning for the link between the PSM and the TCO, including how pivotal the PSM is to the causation pathway of the TCO, and present epidemiological evidence to support this A5.3—Present randomised trial evidence to support the nature of the PSM–TCO comparative treatment effect relationship A5.4—Translate the comparative treatment effect on the PSM from the studies included in Part A, Subsection 2.2, to an estimate of the comparative treatment effect for the TCO.” [22] | Not reported |
CADTH (Canada) | “Validated surrogate outcomes are proven to be predictive of an important patient outcome. A surrogate outcome is valid only if there is a “strong, independent, consistent association” with an important patient outcome, and there is “evidence from randomized trials that … improvement in the surrogate end point has consistently lead to improvement in the target outcome.” [24] | Not reported |
DIMDI (Germany) | No gold standard for the validation of surrogate endpoints, but approaches based on several studies, such as meta-analyses, are preferred Regardless of statistical method used for validation, validation should be considered as technology specific [25] | Not reported |
G-BA (Germany) | Correlation from meta-analyses between effects on the surrogate outcome and the final outcome [39, 40] Surrogate Threshold Effect [41] | Not reported |
IQWiG (Germany) | No ‘best’ method is defined, but correlation-based validation is the ‘preferred’ method, in the sense it has been most widely used in evaluations. Another option discussed is the surrogate threshold effect [26] A support document [27] discusses threshold values reported in the literature, without enforcing them | “A correlation of R ≥ 0.85; R2 ≥ 0.72 measured at the lower bound of the 95% percentage interval allows to conclude that the validation study represents a high reliable result. This interval R < 0.85; R2 < 0.72 to R > 0.7; R2 > 0.49 represents a medium reliable result between surrogate and patient-relevant endpoint. If a validation study shows high reliable results with statistically low correlation (R ≤ 0.7; R2 ≤ 0.49) measured at the lower bound of the confidence interval then the surrogate is not considered as a valid endpoint” [27] |
EUnetHTA | Correlation from meta-analyses of several RCTs between the effects on the surrogate and the effects on the clinical endpoint If there is no high correlation demonstrated, conclusions might still be made if the surrogate threshold effect is considered [41] | “Values of between about 0.85 and 0.95 are often discussed” |
AOTMiT (Poland) | “If the clinical effectiveness assessment is based on the results of surrogate endpoints, the clinical analysis must reliably demonstrate their relationship with the clinically significant outcomes. Validation of the surrogate endpoints should be carried out in relation to the health problem in question.” Cites EUNetHTA guidelines for methods | Not reported |
INFARMED (Portugal) | Seems to use the framework proposed by Bucher et al. [14] “For a surrogate measure to be validated, the following questions should be positively answered: 1. Does a strong, consistent and independent association exist between the surrogate outcome and the clinically relevant outcome? This criterion is necessary but not sufficient in itself; 2. Are there any randomized studies on the same class of medicines, where improvements in the surrogate outcomes corresponded to improvements in clinically relevant outcomes? 3. Are there any randomized studies on different classes of medicines, where improvements in the surrogate outcomes corresponded to improvements in clinically relevant outcomes for the patient?” | To be considered as validated, a surrogate outcome must comply with criteria from 1 to 3. Verification of these criteria usually requires a meta-analysis of randomized studies |
NICE (UK) | Guidelines are not specific on the validation methods but emphasise that “in all cases, the uncertainty associated with the relationship between the end point and health-related quality of life or survival should be explored and quantified” | Not reported |
3.3.2 Specific Guidance for Disease Areas
3.3.3 Specific Guidance for Medical Devices
NICE TA guidancea | NICE MTEP guidanceb | PBAC | MSAC | |
---|---|---|---|---|
Type of technologies | Pharmaceuticals | Medical devices | Pharmaceuticals | Medical devices |
Use of surrogates considered? | Yes | Yes—although guidance refers broadly to “intermediate outcomes” rather than surrogate endpoints, the guidance acknowledges the limited nature of evidence usually available for medical devices | Yes | Yes |
Surrogate definition provided? | Yes—“intermediate outcome—outcomes that are related to the outcome of interest but may be more easily assessed within a clinical study” | No | Yes—outcomes of RCTs “that are of less patient relevance than intended final outcomes of treatment” | Yes—“a variable that occurs in a causal pathway from a clinical management or factor to the final outcome” |
Examples of surrogates listed? | Yes—“for example, blood pressure reduction is related to the risk of a stroke” | No | Yes—e.g. “viral load and cure of viral hepatitis” | Yes—e.g. “cholesterol for cardiovascular events” |
Acceptability criteria provided? | No—guidance does not provide explicit criteria | No | Yes—“to transform a surrogate outcome to predict a treatment effect on the intended final outcome, explain and justify the method of this transformation, including a justification for how the relationship might vary over time” | Yes—“present a surrogate outcome (that is not the primary outcome) only when it is critical to the therapeutic conclusion or economic evaluation” |
Evidence strength assessment provided? | Yes—while not providing a structured framework, guidance stipulates that “evidence in support of the surrogate-to-final end point outcome relationship must be provided together with an explanation of how the relationship is quantified for use in modelling. The usefulness of the surrogate end point for estimating QALYs will be greatest when there is strong evidence that it predicts health-related quality of life and/or survival. In all cases, the uncertainty associated with the relationship between the end point and health-related quality of life or survival should be explored and quantified” | No | Yes—a three-step framework is proposed: Step 1: provide epidemiological evidence and biological reasoning on the relationship between the surrogate outcome and the final outcome “independent of any intervention” Step 2: provide evidence where similar interventions’ effect on the surrogate outcome predicts an effect on the final outcome Step 3: explain why evidence from previous steps is likely to apply to the proposed technology | Yes—a four-step approach to integrating SE is proposed: “A5.1—Define the [SE] and the [final outcome] A5.2—Establish the biological reasoning for the link between the [SE] and the [final outcome] […] and present epidemiological evidence to support this A5.3—Present randomised trial evidence to support the nature of the [surrogate-final outcome] relationship A5.4—Translate the comparative treatment effect on the [SE] to an estimate of the […] treatment effect for the [final outcome]” |
Validation methods provided? | No | No | Yes—“investigations of heterogeneity, treatment effect variation, subgroup analysis and/or meta-regression” | Yes—multi-trial meta-regression, single trial or small number of randomised trials where individual patient data are available, one randomised trial, no randomised trial data |
Validation cut-off values provided? | No | No | No | No |